.png)
Enlivex
Allocetra immunotherapy now for KNEE OSTEOARTHRITIS/longevity + crypto treasury (Rain Protocol) — sepsis focus dropped; EXCLUDE-recommended
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Enlivex is pivoting from a pure clinical-stage immunotherapy company toward a hybrid model that combines Allocetra development with a prediction-markets treasury strategy, signaling a search for non-dilutive capital and broader optionality.[1][3][17][19] The core operating thesis remains a macrophage-reprogramming platform targeting inflammatory disease and organ failure, but the commercial path is still largely clinical and pre-revenue.[3][8][16]
Efficiency Ratio
The company appears capital-efficient in the sense of maintaining a narrow operational footprint while advancing a multi-indication pipeline, but output is still mostly clinical-stage progress rather than commercial revenue.[4][8][16]
Evidence Signals
Website and investor materials describe a strategic pivot to a "Quality Longevity & Prediction Markets Treasury" model while retaining Allocetra clinical development.
Investor materials state Enlivex is developing Allocetra as a late-stage clinical program for osteoarthritis and other inflammatory indications.
Public company profiles describe Enlivex as a clinical-stage macrophage reprogramming immunotherapy company focused on sepsis and inflammatory conditions.
The company changed its name from Enlivex Therapeutics Ltd. to Enlivex Ltd. in February 2026, reflecting a broader corporate repositioning.
Third-party company profiles report approximately 34 employees, indicating a small operating team.
Pipeline references include Allocetra programs in phase 2 sepsis/organ failure and phase 1/2 osteoarthritis-related indications.
- About
- Israeli biotech company (Enlivex Ltd.; Nasdaq: ENLV; HQ Nes-Ziona, Israel — 14 Einstein St.; ~11-50 staff). As of 2026 Enlivex brands itself 'The Quality Longevity Company,' combining a clinical biotech platform with a prediction-markets crypto-treasury strategy (Rain Protocol). Its clinical asset Allocetra — an off-the-shelf macrophage-reprogramming immunotherapy — is now in development for aging-related diseases, initially focused on knee osteoarthritis. Its earlier sepsis / organ-failure program — the basis on which Enlivex was mapped as a mass-casualty medical countermeasure (C12-09) — is no longer the company's stated focus. Defense relevance has effectively lapsed: the current focus (knee OA / longevity) is not defense-relevant and the company's other pillar is a crypto prediction-markets treasury. Recommended for EXCLUSION from the defense-health map.
- Tags
- #sepsis #celltherapy #macrophage #allocetra #organfailure #medicalcountermeasure #rxbio #dualuse #FLAG-cryptopivot